EGFR Inhibitors in Colorectal Cancer

Ligand Binding and Dimerization Results in TK Activation

EGFR Activation and Signaling Pathways

EGFR Activation Mediates Several Processes

EGFR Expression Correlates With Poor Prognosis in Selected Solid Tumors

Anti-EGFr Monoclonal Antibodies

Properties of Cetuximab

Cetuximab Randomized Pivotal Trial in Metastatic Colorectal Cancer

Cetuximab Randomized Pivotal Trial in Metastatic Colorectal Cancer

Cetuximab/C225 in Colon Cancer

The “Bond” Trials

Cetuximab in the first line?

Monoclonal Antibodies as Targeted Therapy: Evolution to Fully Human Antibody

Panitumumab Phase 2 Study: Monotherapy for CRC - Methods

Panitumumab Phase 2 Study: Monotherapy for CRC - Methods

Panitumumab Phase 2 Study: Monotherapy for CRC – Toxicity

Panitumumab + Chemotherapy 1st Line mCRC Phase 2 Study: Methods

Panitumumab + Chemotherapy 1st Line mCRC Phase 2 Study, Part 1: Skin Toxicity

Panitumumab + Chemotherapy 1st Line mCRC Phase 2 Study, Part 1: Efficacy

Randomized Controlled Phase 3 Trial in mCRC

Study Endpoints

Key Eligibility Criteria

Demographics and Disease Characteristics

Progression-Free Survival

Kaplan- Meier Progression-Free Survival Rates at Prespecified Time Points

Overall Survival – Interim Analysis (All Randomized Analysis Set)

Overall Survival: Censored BSC Patients Who Subsequently Responded After Crossing Over

Safety – Grade 3/4 Adverse Events

Overall Survival by Worst Grade of Skin Toxicity in the Panitumumab Patients

Conclusions and Questions